A known hotspot missense mutation, 104V>M, in the extracellular domain of the kinase ERBB3 (ref. 50) was observed in a single tumour, and antibodies targeting this protein have been in clinical development, including phase II studies. The gene discussed is ERBB3; the disease is neoplasm.